Mozobil

Mozobil is a brand name of plerixafor, approved by the FDA in the following formulation(s):

MOZOBIL (plerixafor - solution; subcutaneous)

• 
  Manufacturer: GENZYME
  
  Approval date: December 15, 2008
  
  Strength(s): 24MG/1.2ML (20MG/ML) ^[RLD]

Has a generic version of Mozobil been approved?

No. There is currently no therapeutically equivalent version of Mozobil available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mozobil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods to mobilize progenitor/stem cells
  Patent 6,987,102
  Issued: January 17, 2006
  Inventor(s): Bridger; Gary J. & Abrams; Michael J. & Henson; Geoffrey W. & MacFarland; Ronald Trevor & Calandra; Gary B. & Broxmeyer; Hal E. & Dale; David C.
  Assignee(s): Anormed, Inc.
  Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.
  
  Patent expiration dates:
  
  
  • July 22, 2023
    
    ✓ 
    Patent use: USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
  
  



• 
  Methods to mobilize progenitor/stem cells
  Patent 7,897,590
  Issued: March 1, 2011
  Inventor(s): Bridger; Gary J. & Abrams; Michael J. & Henson; Geoffrey W. & MacFarland; Ronald Trevor & Calandra; Gary B. & Broxmeyer; Hal E. & Dale; David C.
  Assignee(s): Genzyme Corporation
  Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z′  (1) or pharmaceutically acceptable salt thereof wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system; or Z is of the formula wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms, Z′ may be embodied in a form as defined by Z above, or alternatively may be of the formula —N(R)—(CR2)n—X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.
  
  Patent expiration dates:
  
  
  • July 22, 2023
    
    ✓ 
    Patent use: USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
  
  



• 
  Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
  Patent RE42152
  Issued: February 15, 2011
  Inventor(s): Bridger; Gary J. & Padmanbhan; Sreenivasan & Skerlj; Renato & Thornton; David M.
  Assignee(s): Genzyme Corporation
  Polyamine macrocyclic compounds, e.g. of 10 to 15 ring members and 3 to 6 ring amine nitrogens, linked through methylene groups to an aromatic moiety, show high selective activity against HIV.
  
  Patent expiration dates:
  
  
  • December 10, 2013
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 15, 2013 - NEW CHEMICAL ENTITY
  
  
  • December 15, 2015 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Mozobil Consumer Information (Drugs.com)
• Mozobil Consumer Information (Wolters Kluwer)
• Mozobil Consumer Information (Cerner Multum)
• Mozobil Advanced Consumer Information (Micromedex)
• Plerixafor Consumer Information (Wolters Kluwer)
• Plerixafor Consumer Information (Cerner Multum)
• Plerixafor Subcutaneous Advanced Consumer Information (Micromedex)